A Phase IIb, Randomised, Double-Blind, Placebo-Controlled Study To Assess The Efficacy, Safety And Tolerability Of 24 Weeks Treatment With Different Doses Of AOD9604 Tablets On Weight Loss In Obese Adults.
Completed Phase 2 ACTRN12605000067673
Study Description
Study Details
- Registry ID:
- ACTRN12605000067673
- Conditions:
- Obesity.
- Phase:
- Phase 2
- Target Enrollment:
- 360 participants
- Start Date:
- Age Range:
- 18–65 years
- Healthy Volunteers:
- No
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.